Abstract
Pyrazinamide (PZA) is a key antituberculosis drug, yet no rapid susceptibility test is commercially available. PZA drug susceptibility testing (DST) was performed directly on sputum samples from 327 patients and compared with the indirect method by using the Bactec MGIT 960 system in the context of patient screening for participation in a drug trial. Compared to standard indirect PZA DST, direct DST was successful in only 59% of cases, but results obtained were highly accurate and available faster. Agreement between the direct and indirect methods varied from 90 to 100% in each laboratory. The median times for obtaining PZA results from the time when the specimen was collected ranged from 11 to 16 days for the direct test and 18 to 95 days for the indirect test across laboratories. The direct method is accurate and reproducible across laboratories. It can be expected to accelerate results in >50% of cases, but it cannot replace indirect DST for PZA. Phenotypic methods remain the gold standard for DST in drug trials. If future studies can optimize the method to decrease the number of uninterpretable results, direct MGIT DST could be the new phenotypic DST standard for clinical trials, providing more rapid detection of resistance...Continue Reading
References
May 1, 1988·Diagnostic Microbiology and Infectious Disease·J P LibonatiS H Siddiqi
Feb 21, 2008·Antimicrobial Agents and Chemotherapy·Eric NuermbergerJacques H Grosset
Aug 30, 2008·Journal of Clinical Microbiology·Matsie MphahleleHarleen M S Grewal
Sep 11, 2009·Journal of Clinical Microbiology·S-Y Grace LinSalman Siddiqi
Oct 13, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Gian Cesare GuidiGiuseppe Lippi
Oct 17, 2009·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H AndoT Kirikae
Nov 20, 2009·Journal of Clinical Microbiology·Pamela ChedoreFrances Jamieson
Aug 19, 2010·International Journal of Molecular Sciences·Muthuraj MuthaiahSaroja Veerappan
Sep 21, 2011·Antimicrobial Agents and Chemotherapy·Rokeya TasneenEric L Nuermberger
Dec 14, 2011·Journal of Clinical Microbiology·Salman SiddiqiSabine Rüsch-Gerdes
Apr 4, 2012·Antimicrobial Agents and Chemotherapy·Kathy WilliamsEric L Nuermberger
Jul 26, 2012·Lancet·Andreas H DiaconMelvin K Spigelman
Oct 27, 2012·Journal of Clinical Microbiology·Claudio PiersimoniLanfranco Fattorini
Jul 11, 2013·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ekaterina V KurbatovaJ Peter Cegielski
Aug 21, 2014·The New England Journal of Medicine·Andreas H DiaconUNKNOWN TMC207-C208 Study Group
Mar 22, 2015·Lancet·Rodney DawsonCarl M Mendel
Citations
Nov 16, 2018·Journal of Clinical Microbiology·Roberto AlcántaraPatricia Sheen
Jun 2, 2017·Experimental and Therapeutic Medicine·Peijun TangMeiying Wu
Mar 7, 2020·Journal of Clinical Microbiology·Roberto AlcántaraPatricia Sheen
May 14, 2020·Clinical Chemistry·Ketema TafessGilman Kit Hang Siu
Jun 21, 2017·Scientific Reports·S M Ramirez-BusbyF Valafar
May 18, 2019·Scientific Reports·Muhammad Tahir KhanDong-Qing Wei
Nov 6, 2020·PloS One·Edgar A FlorentiniPatricia Sheen
Jun 3, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Sirus AminiMohammad Mehdi Feizabadi
Jun 19, 2021·New Microbes and New Infections·M J NasiriM Mirsaeidi